

The Implications of Recent Datasets for the Current and Future Management of Breast Cancer — An ASCO 2025 Review

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following measures is recommended to prevent or mitigate oral mucositis in patients receiving datopotamab deruxtecan (Dato-DXd)?
 - a. Systemic corticosteroids
 - b. Steroid mouthwash**
 - c. Inhaled corticosteroids
 - d. No prophylactic measures are recommended when administering Dato-DXd
2. What is the maximum number of cycles of pembrolizumab a patient with metastatic triple-negative breast cancer may receive in the Saci-IO TNBC study?
 - a. 12 cycles
 - b. 24 cycles
 - c. 35 cycles**
 - d. 48 cycles
 - e. Indefinite
3. Which of the following adverse events is most commonly observed in patients receiving sacituzumab govitecan for previously treated advanced breast cancer?
 - a. Oral mucositis
 - b. Dry eye
 - c. Headaches
 - d. Diarrhea**
4. Which of the following rare but serious adverse events has been observed in patients receiving Dato-DXd for previously treated advanced breast cancer?
 - a. Ventricular arrhythmia
 - b. Deep vein thrombosis
 - c. Interstitial lung disease**
 - d. Ischemic stroke
5. The DESTINY-Breast09 study evaluated trastuzumab deruxtecan for breast cancer in which setting?
 - a. With pembrolizumab for relapsed/refractory HER2-low, PD-L1-positive advanced disease
 - b. With pertuzumab as first-line therapy for HER2-positive advanced disease**
 - c. As adjuvant therapy for localized HER2-positive disease after complete resection